Swiss RA registry assessed outcomes after 1st JAKi. 400 RA pts starting/failing JAKi were switched to 2nd JAKi or TNFi

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Swiss RA registry assessed outcomes after 1st JAKi. 400 RA pts starting/failing JAKi were switched to 2nd JAKi or TNFi or other MOA biologic. ~40% had prior bDMARDs. Retention was higher w/ 2nd JAK (918d)i vs other options. TNFi (335d) or OMA (918d). https://t.co/3A3KwVcTCN https://t.co/UFLPGfmzNv
Links
https://wb.md/3XS4sma

Herpes Zoster with JAK Inhibitors A recent review a higher HZ risk with JAKi therapy shows the HZ-risk in RA and UC to

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Herpes Zoster with JAK Inhibitors A recent review a higher HZ risk with JAKi therapy shows the HZ-risk in RA and UC to be higher than PsA when treated with usual doses of TOFA, especially those given higher TOFA doses or concomitant glucocorticoids. https://t.co/BO7CgcuRKR https://t.co/gyMivn5YxL
Links
https://bit.ly/3DVtid9

Is JAKi therapy safe in RA-ILD pts? Italian retrospective study (2018-June 2022) w/ 43 RA pts & HRCT proven ILD (me

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Is JAKi therapy safe in RA-ILD pts? Italian retrospective study (2018-June 2022) w/ 43 RA pts & HRCT proven ILD (med age 69yrs) & Rx w/ JAKi. After 19 mos F/U, the FVC was stable in 79%, improved in 11%, & worse in 11%. DLCO & HRCT trend was similar. https://t.co/bAqa5wKIYE https://t.co/LnlcQtQnm8
Links
https://bit.ly/3Rr6s2r

The EMAs CHMP has recommended granting a marketing authorisation for Sotyktu (deucravacitinib) for the treatment of mode

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
The EMAs CHMP has recommended granting a marketing authorisation for Sotyktu (deucravacitinib) for the treatment of moderate to severe plaque psoriasis in adults. https://t.co/WztKcNDFl1 https://t.co/Cq3Cyr3YqX
Links
https://bit.ly/3JtMv9f

Rretroperitoneal fibrosis Tx is fraut-steroids, tamoxifen, MMF, B cell therapy? OL trial in 8 RPF pts used steroids &am

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Rretroperitoneal fibrosis Tx is fraut-steroids, tamoxifen, MMF, B cell therapy? OL trial in 8 RPF pts used steroids & mTOR inhibitor sirolimus (2mg/d x 3d; 1mg/d); 12 & 48wks - decr in fibrous tissue 50%, ESR 70%, IgG4 50% w/ normalized renal funct. https://t.co/9BJchCctDi
Links
https://bit.ly/3HxfjLz

RANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts - study shows that NFATC1 a

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
RANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts - study shows that NFATC1 associated superenhancer RNA, which is formed during osteoblast differentiation, can be used as a treatment target to reduce erosions https://t.co/gCITdJKPRP https://t.co/HENbYJcOId
Links
https://go.nature.com/3RlShf7
1 February 2023
ACR Urges CMS to Reconsider Copay Assistant Programs in CMS Proposed Rule

The Health and Human Services Notice of Benefit and Payment Parameters proposed rule for 2024 does not revise policies related to copay assistance and patient deductibles.

 The American College of Rheumatology (ACR) today submitted comments to Centers for Medicare and Medicaid Services (CMS) administrator Chiquita Brooks-LaSure urging the agency to reconsider its current policies on essential copay assistance programs that enable patient access to needed treatments.

1 February 2023
Hope for Biologic Treatment of Hidradenitis Suppurativa

A meta-analysis of trials using biologics [adalimumab (ADA), ustekinumab (UST) and secukinumab (SEC)] in the the management of hidradenitis suppurativa (HS) suggests promising results, but more controlled, rigorous studies are needed.

While only adalimumab is currently FDA approved for this inflammatory skin disorder, numerous trials with other biologics exist or are in progress.

Studies in 76 systemic sclerosis (SSc) pts (& animal models of SSc) show fibroblast A20 (enzyme) is downregulated a

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Studies in 76 systemic sclerosis (SSc) pts (& animal models of SSc) show fibroblast A20 (enzyme) is downregulated and promotes fibrosis in SSc; but is repressed by DREAM, an A20 negative transcriptional regulator. https://t.co/30PuO4XRuq https://t.co/VJuAJHGbut
Links
https://go.nature.com/3XWRLq6
Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×